For the quarter ending 2025-12-31, RGBP had -$64,977 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| (increase) decrease in prepaid expenses | - | 0 | -47,562 |
| Net loss | -967,853 | -572,469 | -702,033 |
| Changes in derivative liability | 380,826 | 299,216 | 376,312 |
| Increase (decrease) in interest expense attributable to amortization of discount | 8,850 | 34,234 | 17,914 |
| Common stock issued for expenses | - | 24,386 | 103,714 |
| Common stock issued for compensation | 400,000 | - | - |
| (increase) decrease in accounts receivable | 27,425 | 27,726 | 82,274 |
| Increase (decrease) in accounts payable | 9,310 | 13 | 808 |
| Increase (decrease) in accrued expenses | 29,991 | 63,981 | 109,331 |
| Increase (decrease) in penalties | - | 50,000 | - |
| Increase ( decrease) in unearned income | -31,640 | -31,640 | -94,920 |
| Net cash provided by (used in) operating activities | -197,941 | -160,005 | -223,586 |
| Increase (decrease)in convertible notes payable | 0 | 194,599 | 0 |
| Increase (decrease)in notes payable | -58,836 | - | 0 |
| Borrowings from notes payable to related parties | - | -75,000 | 224,631 |
| Increase (decrease) other liabilities | - | 50,000 | - |
| Common stock issued for cash | 191,800 | 58,200 | 0 |
| Net cash provided by (used in) financing activities | 132,964 | 227,799 | 224,631 |
| Net increase (decrease) in cash | -64,977 | 67,794 | 1,045 |
| Cash and cash equivalents at beginning of period | 69,555 | 716 | - |
| Cash and cash equivalents at end of period | 4,578 | 69,555 | - |
Regen BioPharma Inc (RGBP)
Regen BioPharma Inc (RGBP)